Biopharma M&A maintains strength even as large deals wane
Biopharma's deals landscape could hardly be better, as large companies take a multi-pronged approach to withstand an avalanche of major patent expiries. But there’s one notable missing piece: megadeals. And it may not be coming ...
May 15, 2026 01:56 PM EDT DealsPharma Are pharma megadeals dead? Smaller targets take priority amid hunt for blockbusters Max Bayer Senior Reporter Biopharma’s deals landscape could hardly be better, as large companies take a multi-pronged approach to withstand an avalanche of major patent expiries. But there’s one … Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER
comments(0)
5-min edit window · permanent after that